

RESEARCH

Open Access



Global longitudinal strain for detection of cardiac iron overload in patients with thalassemia: a meta-analysis of observational studies with individual-level participant data

Armin Attar^{1*}, Alireza Hosseinpour¹, Hamidreza Hosseinpour², Nahid Rezaeian³, Firoozeh Abtahi¹, Fereshte Mehdizadeh¹, Mozhgan Parsaee³, Nehzat Akiash⁴, Mohaddeseh Behjati³, Antonella Meloni⁵ and Alessia Pepe⁵

Abstract

Background: Although cardiac magnetic resonance (CMR) is the most reliable tool for assessment of CIO in patients with thalassemia, it is not always readily available. Recent studies have explored the potential of GLS as an alternative for diagnosis of CIO. We aimed to investigate the efficacy of global longitudinal strain (GLS) for detection of cardiac iron level (CIO).

Methods: We searched SCOPUS, MEDLINE, and Embase to identify the studies which used GLS for assessment of CIO. We searched for individual participant data (IPD) in eligible studies to perform ROC curve analysis. CMR with a T2* cut-off value of 20 ms was considered as the gold standard. A meta-analysis was performed and the risk of bias was assessed using the JBI Checklist.

Results: A total of 14 studies with 789 thalassemia patients (310 and 430 with and without CIO respectively and 49 with undetermined condition) were considered eligible for meta-analysis. IPDs of 405 participants were available. GLS was significantly lower in patients with CIO ($-17.5 \pm 2.7\%$) compared to those without CIO ($-19.9 \pm 2.3\%$; WMD = 1.6%, 95% CI = [0.76–2.4], $p = 0.001$, $I^2 = 77.1\%$) and to normal population ($-20.61 \pm 2.26\%$; WMD = 2.2%, 95% CI = [0.91–3.5], $p = 0.001$, $I^2 = 83.9\%$). A GLS $< -19.5\%$ could predict CIO with 92.8% sensitivity and 34.63% specificity (AUC = 0.659, 95% CI = [0.6–0.72], p -value < 0.0001). A GLS value $< -6\%$ has 100% positive predictive and $\geq -24.5\%$ has 100% negative predictive values for detection of CIO.

Conclusions: According to our study, GLS is a strong predictor of CIO and when CMR is not available, it may be a useful screening method for identification of CIO in thalassemia patients.

Keywords: Thalassemia, Iron overload, Speckle tracking, Global longitudinal strain

*Correspondence: attar@sums.ac.ir

¹ Department of Cardiovascular Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.


Graphical Abstract

Global longitudinal strain for detection of cardiac iron overload in patients with thalassemia: a meta-analysis of observational studies with individual-level participant data

Aim To investigate the efficacy of global longitudinal strain (GLS) for detection of cardiac iron overload (CIO) in patients with thalassemia

Study design and data sources A meta-analysis of observational studies with individual-level participant data (IPD)

14 studies with 789 thalassemia patients and IPD from 405 patients



- ◆ GLS was significantly lower in patients with CIO (-17.5±2.7%) compared to patients with no CIO (-19.9±2.3%)
- ◆ GLS <-19.5% can predict CIO with 92.8% sensitivity and 34.63% specificity

Background

Cardiomyopathy induced by iron deposition in patients with thalassemia is a reversible phenomenon when iron chelation therapy is started on time. Therefore, early detection of cardiac iron overload (CIO) in the prevention of progressive heart failure is vital [1, 2]. Cardiac magnetic resonance (CMR) imaging has been proposed as the most reliable and sensitive non-invasive tool to evaluate the iron level of myocardium [3–5]. Values of T2* less than 20 and 10 ms are indicative of CIO and severe CIO, respectively. A study has estimated the prevalence of CIO in magnetic resonance imaging (MRI) to be 25% [6]. Cardiac T2* values have a prognostic role, allowing the identification of thalassemia patients at risk for cardiac complications and needing an intensification of chelation therapy [7]. However, CMR for iron overload screening in patients with thalassemia has the disadvantages of limited availability and high costs [8]. This

emphasizes the importance of finding alternative tools to investigate the state of cardiac iron overload.

Previous studies have shown the benefits of novel echocardiographic techniques such as strain imaging and tissue imaging [9, 10] for detection of early and subclinical myocardial dysfunction syndromes. Speckle-tracking echocardiography (STE) is a novel imaging technique for evaluating the myocardial function and diagnosing the deformation of myocardium using exclusive parameters including three strain components- longitudinal, circumferential, and radial [9, 10]. Recently, STE has been used for early detection of ventricular dysfunction in patients with transfusion dependent thalassemia (TDT) [11]. Longitudinal strain was found to be significantly different among patients with β-thalassemia major and healthy subjects in several studies [12–14]. Furthermore, global longitudinal strain (GLS) has been proposed as a novel predictor of CIO in patients with TDT and hence,

a promising alternative for cardiac T2*. However, most of the studies have only done a correlation assessment between GLS and CMR T2* values. Nevertheless, a more important question is that how these echocardiographic findings differ in patients with a cardiac MRI T2* values less than 20 ms, as an indicator of myocardial iron deposition. A few studies with limited sample size have performed ROC curve analysis to find appropriate cut off values and have suggested different GLS cut-off values for detection of cardiovascular involvement [15–17]. Therefore, in this study we aimed to find a more precise GLS cut-off value using individual participant data analysis. Also, available echocardiographic parameters such as GLS and left ventricular ejection fraction (LVEF) were analyzed to see if there is any correlation between CIO and echocardiographic markers.

Methods

Protocol

This study was registered with PROSPERO (registration number: CRD42021230361) and conducted according to the recommendations provided by Preferred Reporting Items for a Systematic Review and Meta-Analysis of Individual Participant Data (PRISMA-IPD) statement 2015 [18].

Eligibility criteria

Eligible studies were all the original observational articles which compared the parameters of two-dimensional and three-dimensional speckle tracking echocardiography including GLS and LVEF between subgroups of patients with β -thalassemia major based on their cardiac T2* values (T2* \geq 20 ms identifying patients with no CIO and T2* < 20 ms identifying thalassemia patients with CIO). The studies which only compared the CMR imaging parameters or echocardiographic data between patients with thalassemia and healthy subjects were excluded from the present meta-analysis since they did not divide thalassemia patients based on their CIO status.

Search strategy

We performed a categorized and comprehensive search in electronic databases including SCOPUS, MEDLINE and Embase. The primary search was run on 10th of January 2020 and it was updated on 30th of October 2021. No specific restriction was applied to our search and the sample size. All the articles with no time limits were included. Only the studies in the English language with available full-text were included as eligible. Additional relevant studies were identified through the references list of the included articles. The following keywords were searched: (Thalassemia) AND ((cardiomyopathy) OR (cardiac iron

overload) OR (echocardiography) OR (cardiac MRI) OR (global longitudinal strain) OR (speckle-tracking). The related PRISMA flow diagram is illustrated in Fig. 1.

Study selection

Two investigators (AA, AH) screened the titles and abstracts for relevant studies. After removing the duplicates, studies that did not meet the selection criteria through reviewing titles or/and abstracts were excluded. For potential relevant studies and for articles with unclear eligibility, the full text was reviewed. Any conflicts were resolved by discussion between the two reviewers (AA, AH); in case of further disagreements, a third party would decide.

Data collection

Individual participant data (IPD) of eligible studies were requested to be included in our meta-analysis. We contacted the corresponding authors via email and explained the study goals and asked for their raw data on the participants' values (GLS and T2*) for generating a ROC curve and providing cut-off value with sensitivity and specificity as well as baseline characteristics including age and sex. A reminder email was sent to all the corresponding authors 2 weeks after the initial email if they did not respond. The received data were merged into one dataset and one of the authors (AA) explored the received data integrity by doing internal consistency checks. Also, for additional analyses, sample size as well as all available echocardiographic parameters were gathered by one of the reviewers (AH) from both groups with thalassemia (T2* \geq 20 and T2* < 20) and also in the control groups if available.


Risk of bias assessment

We assessed the quality of the selected studies using the JBI Checklist for Diagnostic Test Accuracy Studies which comprises 10 questions [19, 20]. The possible answers to the questions include *Yes*, *No*, *Unclear* or *Not Applicable*. Two investigators (AA, AH) checked the risk of bias using the mentioned tool.

Data synthesis and statistical analysis

A one-stage individual participant data meta-analysis was performed using the data collected from the available studies on GLS to create a receiver-operating characteristic (ROC) curve. We used Youden index to calculate an optimal threshold (cut-off) in addition to its sensitivity and specificity. Also, area under the curve (AUC), standard error (SE), and 95% confidence interval (CI) were reported for the results.

Additional analyses were also conducted. Values of echocardiographic markers including GLS, left ventricular



ejection fraction (LVEF), global circumferential strain (GCS), global radial strain (GRS), E/A, E/E', and deceleration time between patients with thalassemia with and without evident cardiac iron overload based on their CMR T2* were pooled for generating forest plots and calculating the weighted mean difference (WMD) and 95% CI with DerSimonian and Laird method. Another analysis was made to compare the markers GLS and LVEF between the healthy subjects and thalassemia patients as well. The magnitude of heterogeneity was estimated using I² and values of 25%, 50%, and 75% were considered low, moderate, and high degree of inconsistency, respectively. Random effects model was used for all the analyses. For possible publication bias, Egger's test and related funnel plots were evaluated. A p-value of <0.05 was considered significant for all the analyses. All the statistical analyses were conducted

using Stata software version 14.2 (StataCorp LP, College Station, TX, USA) and MedCalc program version 19.6.1 (MedCalc Software Ltd, Ostend, Belgium).

Results

Study selection and included studies characteristics

After an initial search through the databases, 5609 records were identified for screening. Following the removal of duplicates, titles and abstracts of the remaining studies were investigated and irrelevant or ineligible records were eliminated. Finally, 14 studies with 789 thalassemia participants (310 and 430 with and without CIO respectively and 49 with undetermined condition) met all the eligibility criteria for the systematic review and meta-analysis [15–17, 21–31] (Table 1 summarized their characteristics) (Fig. 1). Eight studies with 405

Table 1 Characteristics of the 14 eligible studies for meta-analysis

Studies	Year of publication	Country	Age	Male (%)	No. of patients		Echocardiographic data			
					T2* ≥ 20	T2* < 20	GLS		LVEF	
							T2* ≥ 20	T2* < 20	T2* ≥ 20	T2* < 20
Pizzino et al. [21]	2017	Italy	37.4 ± 10	53%	22	6	21.3 ± 2.7	18.3 ± 2	60.2 ± 4.8	58 ± 2.4
Parsaee et al. [15]	2018	Iran	30.79 ± 9.37	45%	81	41	-19 (-18 to -20)	-17 (-19 to -16)	63 (59-68)	58 (53-63)
Abtahi et al. [22]	2019	Iran	23.7 ± 5	56%	28	22	21.55 ± 2.68	17.64 ± 2.56	58.5 ± 5	59.32 ± 4.9
Ari et al. [16]	2017	Turkey	13.3 ± 16.1	50%	20	10	-23.10 ± 2.20	-19.70 ± 3.10	68.3 ± 3.5	
Rezaeian et al. [17]	2020	Iran	24.66 ± 6.23	57.1%	25	66	-13.81 ± 3.25	-12.9 ± 4.18	52.0 ± 12.4	
Hanneman et al. [23]	2016	Canada	34.6 ± 9.5	53%	11	19	-18.8 ± 3.5	-19.4 ± 1.8	58.5 ± 5.5	60.4 ± 4.4
Parsaee et al. [24]	2019	Iran	31.96 ± 7.5	44.4%	25	20	-22.36 ± 2.34	-21.73 ± 1.71	-	
Garceau et al. [25]	2011	Canada	34.4 ± 11	46.6%	23	22	-20 ± 2	-16 ± 3	64 ± 5	59 ± 7
Nadar et al. [26]	2020	Oman	26.3 ± 6.1	42.8%	61	23	-19.2 ± 2.8	-18.6 ± 2.4	59.5 ± 6.7	60.4 ± 5.2
El-Shanshory et al. [4]	2020	Egypt	10.9 ± 3.7	66.6%	68	32	-21.23 ± 2.68	-21.375 ± 2.06	54.88 ± 12.47	49.88 ± 14.04
Djer et al. [28]	2020	Indonesia	13-41	50%	16	14	-	-	65.6 (60.6-75.5)	64.8 (60.5-75)
Barzin et al. [29]	2012	Iran	23.5 (15-37)	48.4%	16	14	-	-	60.3 ± 3.99	51.1 ± 4.39
Poorzand et al. [30]	2019	Iran	23.51 ± 6.2	52.35%	30	14	-20.28 ± 1.67	-18.23 ± 3.41	58.6 ± 2.87	56.05 ± 8.8
Odoardo et al. [31]	2017	Italy	36.6 ± 7	38.2%	34	21	-19.2 ± 3	-18.8 ± 2.6	61 ± 5.3	60.6 ± 6.2

patients with β -thalassemia accepted to share their data to be analyzed for IPD [12, 15, 17, 21, 22, 24, 30, 31]. It is important to note that some authors have provided us with data from more number of patients than those used in their original investigation.

Global longitudinal strain

The pooled mean \pm standard deviation (SD) GLS was -17.48 ± 2.69 and -19.88 ± 2.33 , respectively in thalassaemic patients with and without CIO. Comparison of GLS between the thalassaemic groups with and without CIO showed that GLS was significantly lower in patients with CIO compared to those without CIO (WMD = 1.60, 95% CI = [0.76–2.45], $p = 0.001$, $I^2 = 77.1\%$) (Fig. 2a). Heterogeneity decreased from 77.1% to 52.3% after subtraction

of outliers although excluding the outliers diminished the level of association (WMD = 0.90, 95% CI = [0.25–1.55], $p = 0.007$). Also the mean \pm SD GLS in the control group was -20.61 ± 2.26 and the difference between the control and thalassaemia groups with overload was also found to be significant (WMD = 2.20, 95% CI = [0.91–3.50], $p = 0.001$, $I^2 = 83.90\%$) (Fig. 2b). After excluding the outliers the level of heterogeneity decreased from 83.9% to 48% but the level of association remained high (WMD = 1.58, 95% CI = [0.79–2.37], $p = 0.001$).

Meta-analysis of the IPD showed a cardiac iron overload prevalence of 35.1%. Characteristic ROC curve analysis revealed that an optimal cut-off value of -19.5 for GLS could predict the cardiac iron overload in patients with thalassaemia with 92.8% sensitivity and 34.63%




Fig. 2 Forest plot of comparison of GLS between **a** patients with β -thalassemia with CIO and without any evident CIO and **b** control group and patients with thalassaemia **c** ROC curve analysis of GLS (a cut-off value of -19.5 could be employed for early detection of myocardial iron overload in patients with β -thalassaemia)





Fig. 3 Forest plot of the comparison of LVEF between **a** thalassemic participants with and without CIO and **b** healthy subjects and thalassemic group

specificity (AUC = 0.659, SE = 0.0291, 95% CI = [0.60–0.72], p -value < 0.0001) (Fig. 2c). A GLS value < -6 had 100% positive predictive and \geq -24.5 had 100% negative predictive value for detection of CIO.

Left ventricular ejection fraction

Pooled mean \pm SD of LVEF in the thalassemic groups with and without CIO and also control group was 57.74 \pm 6.92, 60.12 \pm 6.84, and 62.38 \pm 4.13, respectively. No significant differences were observed regarding LVEF in patients with thalassemia with and without CIO (WMD = -2.38, 95% CI = [-4.83–0.06], p = 0.056, I^2 = 80.5%) (Fig. 3a) Subtracting outliers reduced the level of heterogeneity from high to low (I^2 = 0.0%) (WMD = 0.22, 95% CI = [-1.12–1.55], p = 0.752). Also between healthy subjects and thalassemia groups with CIO (WMD = -2.42, 95% CI = [-5.59–0.74], p = 0.133, I^2 = 78.6%) (Fig. 3b). The level of heterogeneity remained high after removing outliers (I^2 = 71.9%).

Other echocardiographic parameters

There was a significant correlation between lower levels of GCS and myocardial iron overload (WMD = 2.69, 95% CI = [1.41–3.97], p < 0.001, I^2 = 22.3%) with possible publication bias according to Egger’s test (p = 0.016) although evaluation of trim-and-fill method showed minimal evidence for publication bias (Fig. 4). In contrast, no difference was found regarding the values of GRS between the two groups of thalassemia (WMD = -3.853, 95% CI = -7.796 to 0.091, p = 0.055, I^2 = 0.00%) (Supplementary material, Figure-S1). E/A ratio and E/E’ ratio comparison did not reach a significant level between

the two groups (E/A: WMD = 0.159, 95% CI = -0.104 to 0.422, p = 0.237, I^2 = 84.4%) (Supplementary material, Figure-S2) (E/E’: WMD = 1.006, 95% CI = -1.574 to 3.585, p = 0.445, I^2 = 95.6%) (Supplementary material, Figure-S3). No correlation was also observed regarding the deceleration time between the two thalassemia groups (WMD = -5.343, 95% CI = -38.906 to 28.221, p = 0.755, I^2 = 92.0%) (Supplementary material, Figure-S4).

Risk of bias of the included studies

After evaluating the quality of the eligible studies using JBI Checklist, we decided to include all the studies in the meta-analysis due to their high-quality. Table 2. summarizes the risk of bias assessment of the eligible studies.

Evaluation of the funnel plots for the main outcomes (GLS and LVEF) demonstrated the presence of asymmetrical distribution among the studies (Supplementary material, Figure-S5, 6, 7, 8). However, p -values of Egger’s test did not reach a significant level for publication bias (p = 0.144 for GLS between thalassemia patients with and without CIO, p = 0.510 for GLS between thalassemia and control group, p = 0.777 for LVEF between thalassemia patients with and without CIO, p = 0.263 for LVEF between the thalassemia and control group). For sensitivity analysis, we removed each single study from all the analyses to see their impact on the summary of results and no significant change was observed for all the parameters.

Discussion

Here for the first time, we performed a meta-analysis to evaluate the efficacy of speckle tracking echocardiography for detection of CIO using IPD and found that GLS




Fig. 4 Forest plot of comparing GCS between patients with thalassemia with and without CIO

Table 2 Quality assessment of the included studies using JBI Checklist for Diagnostic Test Accuracy Study

Studies	(1) Random sampling	(2) Avoidance of case control design	(3) Avoidance of inappropriate exclusions	(4) Blinded interpretation of index test results	(5) Use of pre-specified threshold	(6) Reference standard correctly classifies the target condition	(7) Blinded interpretation of reference standard	(8) Appropriate interval between index test and reference standard	(9) Patients receiving the same reference standard	(10) All the patients including in the analysis
Parsaee et al. [15]	No	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Ari et al. [16]	No	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Rezaeian et al. [17]	Yes	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Pizzino et al. [21]	No	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Hanneman et al. [23]	Yes	No	Yes	Unclear	Yes	Yes	Yes	Unclear	Yes	Yes
Parsaee et al. [24]	No	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Garceau et al. [25]	No	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Abtahi et al. [22]	Yes	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Nadar et al. [26]	Yes	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
El-Shanshory et al. [4]	Yes	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Djer et al. [28]	Yes	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Barzin et al. [29]	No	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Poorizand et al. [30]	Yes	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes
Odoardo et al. [31]	No	No	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes

might be a promising tool for detection of this pathology. We used a T²* CMR value of 20 ms as the gold standard and found that GLS was significantly lower in patients with CIO (-17.5±2.7) compared to those without CIO (-19.9±2.3) and to normal population (-20.6±2.3). According to IPD analysis, a GLS<-19.5 could predict CIO with a sensitivity of 92.8% and specificity of 34.63%. A GLS value <-6 had 100% positive predictive and ≥ -24.5 had 100% negative predictive value for detection of CIO.

Although CMR imaging is the most accurate non-invasive technique for diagnosis of myocardial iron overload, it has some limitations and disadvantages. Cardiac MRI is a time-consuming and costly technique and it is not the most accessible option compared to other diagnostic techniques including echocardiography in all regions of the world [8]. Several studies have evaluated the correlation between echocardiographic parameters and CMR findings. A study conducted by Aypar et al. on septal systolic myocardial (S_m) velocity and septal early diastolic myocardial (E_m) velocity showed a significant relationship with T₂* [32]. In another study by Magri et al. [33], systolic strain of right ventricular free wall, systolic strain of the septal wall, and systolic strain of lateral wall were significantly associated with T₂*. However, despite the importance of the mentioned findings, the most important correlations to investigate are those with cardiac MRI T₂* values less than 20 ms as an indicator of myocardial iron overload. Pizzino and colleagues found that GLS showed a significant correlation with T₂* values (R=-0.49; P=0.001), and it was significantly lower in patients with a T₂* value lower than 20 ms (-18.3±2 vs. -21.3±2.7

[21]. Garceau and colleagues found a strong and direct logarithmic relationship between GLS and T₂* [25]. Similar findings were noted in other studies [12, 15, 22]. On the contrary, some other studies did not find such correlation between CMR T₂* and GLS [23, 24, 26]. Our analysis showed that GLS was significantly lower in patients with iron deposition than those without it and normal healthy population. However, it is very important to find a cut off value based on which diagnosis or exclusion of CIO can be done.

In the present study, we sought to establish a cut-off value using IPD meta-analysis for STE markers to help diagnose CIO in thalassemia patients. Our analysis revealed that A GLS value less than 6% was diagnostic for CIO, and ≥ -24.5% could reliably rule out the presence of CIO. Also, a threshold value of less than -19.5% with a 92.8% sensitivity and 34.63% specificity can be used for screening purposes due to its high sensitivity. It is noteworthy that although this cut-off value represents a high sensitivity for detection of CIO, it should be practiced with caution since it has a low level of specificity. Only a few studies have performed a ROC curve analysis to find a cut off value. Pizzino and colleagues showed that patients with impaired GLS (< -19.5%) had a significant higher risk of showing significant cardiac iron deposition (Odds ratio = 17) [21]. Similarly, Abtahi et al. [22] found that a GLS threshold of 19.5, as the cut off value, could detect Iron deposition with a sensitivity of 82.14% and specificity of 86.36%. Based on the findings from this study, an algorithm (Fig. 5) may be suggested to




Fig. 5 Proposed algorithm for using GLS measurement to screen cardiac Iron overload (CIO). Note that for better understanding, the GLS values are mentioned in their absolute numerical form

explain how to use speckle tracking echocardiography and GLS measurement for screening and detection of myocardial iron overload.

This study had some limitations. First, we could not find IPD from all the studies. Furthermore, it is known that different echocardiography machines use various software and may produce unequal final GLS results and since we have performed a met-analysis this issue could not be addressed. In addition, all studies were cross-sectional and we were unable to show whether early detection of cardiac iron overload with GLS can be translated into a higher risk of heart failure in the future.

Conclusions

Recent studies have explored the potential of STE markers for early detection of CIO in individuals with β -thalassemia to prevent iron deposition induced heart failure. Among all the candidates, in this meta-analysis we showed that GLS was the most favorable echocardiographic marker in diagnosing CIO. Furthermore, we provided a ROC curve and reliable cut-off value for GLS that can be employed for detection of CIO in patients with β -thalassemia using IPD meta-analysis.

Abbreviations

CIO: Cardiac iron level; CMR: Cardiac magnetic resonance; GLS: Global longitudinal strain; IPD: Individual participant data; MRI: Magnetic resonance imaging; EF: Ejection fraction; FS: Fractional shortening; STE: Speckle-tracking echocardiography; GCS: Global circumferential strain; GRS: Global radial strain; ROC: Receiver-operating characteristic; WMD: Weighted mean difference; AUC: Area under the curve; SE: Standard error; CI: Confidence interval; LVEF: Left ventricular ejection fraction; GRS: Global radial strain; TDT: Transfusion dependent thalassemia.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12947-022-00291-4>.

Additional file 1: Figure-S1. Forest plot of comparison of GRS between thalassemia groups with and without CIO.

Additional file 2: Figure-S2. Forest plot of comparison of E/A between thalassemia groups with and without CIO.

Additional file 3: Figure-S3. Forest plot of comparison of E/E' between thalassemia groups with and without CIO.

Additional file 4: Figure-S4. Forest plot demonstrating comparison of deceleration time between thalassemia groups with and without CIO.

Additional file 5: Figure-S5. Funnel plot of GLS between thalassemic groups.

Additional file 6: Figure-S6. Funnel plot of GLS between thalassemic groups with CIO and healthy participants.

Additional file 7: Figure-S7. Funnel plot of LVEF between thalassemic groups.

Additional file 8: Figure-S8. Funnel plot of LVEF between thalassemic groups with CIO and healthy participants.

Acknowledgements

The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran and also [Center for Development of Clinical Research of Nemazee Hospital and Dr. Nasrin Shokrpour](#) for editorial assistance.

Authors' contributions

AA and AH contributed to concept and design of the study. AH performed the data analysis. HH, NH, FA, FM, MP, NA, MB, AM, and AP performed the data interpretation. All the authors contributed to drafting and revising of the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by the grant number 24954 from vice chancellor of research from Shiraz University of Medical Sciences.

Availability of data and materials

The data underlying this article will be shared on reasonable request to the corresponding author.

Declarations

Ethical approval and consent to participate

The study protocol was approved by ethic committee of Shiraz University of Medical Sciences (IR.SUMS.MED.REC.1400.225.).

Consent for publication

Not applicable.

Competing interests

None.

Author details

¹Department of Cardiovascular Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ²Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ³Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. ⁴Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ⁵Gabriele Monasterio Foundation, Tuscan Region, Pisa, Italy.

Received: 8 March 2022 Accepted: 2 August 2022

Published online: 12 August 2022

References

1. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. *Hematology Am Soc Hematol Educ Program*. 2017;2017(1):265–71.
2. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, et al. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. *Circ Heart Fail*. 2010;3(3):451–8.
3. Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients. *Expert Rev Hematol*. 2018;11(6):471–9.
4. El-Shanshory M, Tolba O, El-Shafiey R, Elgamasy M, Hablas N, Mawlana W. Cardiac Iron Overload by MRI in Children With B-Thalassemia Major and its Correlation With Cardiac Function by Echocardiography. *J Pediatr Hematol Oncol*. 2020;42(6):398–402.
5. Meloni A, Maggio A, Positano V, Leto F, Angelini A, Putti MC, et al. CMR for myocardial iron overload quantification: calibration curve from the MIOT Network. *Eur Radiol*. 2020;30(6):3217–25.
6. Koohi F, Kazemi T, Miri-Moghaddam E. Cardiac complications and iron overload in beta thalassemia major patients-a systematic review and meta-analysis. *Ann Hematol*. 2019;98(6):1323–31.
7. Pepe A, Meloni A, Rossi G, Midiri M, Missere M, Valeri G, et al. Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach. *Eur Heart J Cardiovasc Imaging*. 2018;19(3):299–309.

8. Saeed M, Van TA, Krug R, Hetts SW, Wilson MW. Cardiac MR imaging: current status and future direction. *Cardiovascular diagnosis and therapy*. 2015;5(4):290.
9. Bansal M, Kasliwal RR. How do I do it? Speckle-tracking echocardiography *Indian heart journal*. 2013;65(1):117–23.
10. Cameli M, Mondillo S, Galderisi M, Mandoli GE, Ballo P, Nistri S, et al. [Speckle tracking echocardiography: a practical guide]. *G Ital cardiol*. 2017;18(4):253–69.
11. Li SJ, Hwang YY, Ha SY, Chan GC, Mok AS, Wong SJ, et al. Role of Three-Dimensional Speckle Tracking Echocardiography in the Quantification of Myocardial Iron Overload in Patients with Beta-Thalassemia Major. *Echocardiography*. 2016;33(9):1361–7.
12. Parsaee M, Saedi S, Joghataei P, Azarkeivan A, Alizadeh SZ. Value of speckle tracking echocardiography for detection of clinically silent left ventricular dysfunction in patients with β -thalassemia. *Hematology (Amsterdam, Netherlands)*. 2017;22(9):554–8.
13. Cheung YF, Liang XC, Chan GC, Wong SJ, Ha SY. Myocardial deformation in patients with Beta-thalassemia major: a speckle tracking echocardiographic study. *Echocardiography (Mount Kisco, NY)*. 2010;27(3):253–9.
14. Piccione MC, Piraino B, Zito C, Khandheria BK, Di Bella G, De Gregorio C, et al. Early identification of cardiovascular involvement in patients with β -thalassemia major. *Am J Cardiol*. 2013;112(8):1246–51.
15. Parsaee M, Akiash N, Azarkeivan A, Alizadeh Sani Z, Amin A, Pazoki M, et al. The correlation between cardiac magnetic resonance T2* and left ventricular global longitudinal strain in people with β -thalassemia. *Echocardiography*. 2018;35(4):438–44.
16. Ari ME, Ekici F, Çetin İ, Tavil EB, Yaralı N, Işık P, et al. Assessment of left ventricular functions and myocardial iron load with tissue Doppler and speckle tracking echocardiography and T2* MRI in patients with β -thalassemia major. *Echocardiography*. 2017;34(3):383–9.
17. Rezaeian N, Mohtasham MA, Khaleel AJ, Parnianfard N, Kasani K, Golshan R. Comparison of global strain values of myocardium in beta-thalassemia major patients with iron load using specific feature tracking in cardiac magnetic resonance imaging. *Int J Cardiovasc Imaging*. 2020;36(7):1343–9.
18. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA*. 2015;313(16):1657–65.
19. Campbell JM, Klugar M, Ding S, Carmody DP, Hakonsen SJ, Jadotte YT, et al. Diagnostic test accuracy: methods for systematic review and meta-analysis. *JBI Evidence Implementation*. 2015;13(3):154–62.
20. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155(8):529–36.
21. Pizzino F, Meloni A, Terrizzi A, Casini T, Spasiano A, Cosmi C, et al. Detection of myocardial iron overload by two-dimensional speckle tracking in patients with beta-thalassaemia major: a combined echocardiographic and T2* segmental CMR study. *Int J Cardiovasc Imaging*. 2018;34(2):263–71.
22. Abtahi F, Abdi A, Jamshidi S, Karimi M, Babaei-Beigi MA, Attar A. Global longitudinal strain as an Indicator of cardiac Iron overload in thalassemia patients. *Cardiovasc Ultrasound*. 2019;17(1):24.
23. Hanneman K, Nguyen ET, Thavendiranathan P, Ward R, Greiser A, Jolly M-P, et al. Quantification of myocardial extracellular volume fraction with cardiac MR imaging in thalassemia major. *Radiology*. 2016;279(3):720–30.
24. Parsaee M, Pouraliakbar H, Azarkeivan A, Ghadrdoost B, Behjati M. The Role of Exercise Stress Echocardiography for Determination of Subclinical Cardiac Involvement in β -Thalassemia Major. *Hemoglobin*. 2019;43(1):34–7.
25. Garceau P, Nguyen E, Carasso S, Ross H, Pendergrast J, Moravsky G, et al. Quantification of myocardial iron deposition by two-dimensional speckle tracking in patients with β -thalassaemia major and Blackfan-Diamond anaemia. *Heart*. 2011;97(5):388–93.
26. Nadar SK, Daar S, Abdelmottaleb WA, Shaikh MM, Al Mahrouqi H, Al-Raiisi M, et al. Abnormal diastolic function and Global longitudinal strain in patients with Thalassemia Major on long term chelation therapy. *Int J Cardiovasc Imaging*. 2021;37(2):643–9.
27. El-Shanshory M, Tolba O, El-Shafey R, Elgamasy M, Hablas N, Mawlana W. Cardiac iron overload by MRI in children with β -thalassemia major and its correlation with cardiac function by echocardiography. *J Pediatr Hematol Oncol*. 2020;42(6):398–402.
28. Djer MM, Anggriawan SL, Gatot D, Amalia P, Sastroasmoro S, Widjaja P. Correlation between T2* cardiovascular magnetic resonance with left ventricular function and mass in adolescent and adult major thalassemia patients with iron overload. *Acta Med Indones*. 2013;45(4):295–301.
29. Barzin M, Kowsarian M, Akhlaghpour S, Jalalian R, Taremi M. Correlation of cardiac MRI T2* with echocardiography in thalassemia major. *Eur Rev Med Pharmacol Sci*. 2012;16(2):254–60.
30. Poorzand H, Manzari T, Vakilian F, Layegh P, Badiie Z, Norouzi F, et al. Longitudinal strain in beta thalassemia major and its relation to the extent of myocardial iron overload in cardiovascular magnetic resonance. *Archives of Cardiovascular Imaging*. 2017;5(1):1–.
31. Di Odoardo LAF, Giuditta M, Cassinerio E, Roghi A, Pedrotti P, Vicenzi M, et al. Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population. *Intern Emerg Med*. 2017;12(6):799–809.
32. Aypar E, Alehan D, Hazirolan T, Gümrük F. The efficacy of tissue Doppler imaging in predicting myocardial iron load in patients with beta-thalassemia major: correlation with T2* cardiovascular magnetic resonance. *Int J Cardiovasc Imaging*. 2010;26(4):413–21.
33. Magri D, Sciomer S, Fedele F, Gualdi G, Casciani E, Pugliese P, et al. Early impairment of myocardial function in young patients with beta-thalassemia major. *Eur J Haematol*. 2008;80(6):515–22.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

